这家减重药公司股价大涨

Group 1 - Federal Pharmaceutical's stock price surged over 7% following the announcement of mid-term clinical trial data for its new weight loss drug UBT251, which showed an average weight loss of 19.7% in the treatment group compared to 2% in the placebo group after 24 weeks of treatment [2] - Novo Nordisk entered a licensing agreement with Federal Pharmaceutical for UBT251 in March last year, with an upfront payment of $200 million and a potential total deal value of up to $2 billion [2] - UBT251 targets GLP-1/GIP/GCG triple receptors and is expected to outperform Eli Lilly's dual-target GLP-1 weight loss drug [2] Group 2 - Novo Nordisk has initiated a global trial involving approximately 330 overweight or obese patients using different doses of UBT251, with results expected in 2027, and plans to start a trial for type 2 diabetes patients [3] - In a competitive landscape for weight loss drugs, multinational pharmaceutical companies are increasingly focusing on Chinese weight loss drug assets, as evidenced by recent strategic collaborations, including one between Senwa Bio and Pfizer China, with a total deal value of up to nearly $500 million [3] - Pfizer also secured a licensing agreement with a subsidiary of Fosun Pharma for a GLP-1 receptor agonist, with a total deal value exceeding $2 billion [3] Group 3 - In July last year, CSPC Pharmaceutical licensed an oral small molecule GLP-1 receptor agonist to Madrigal Pharmaceuticals for $2.075 billion, and earlier this year, it licensed another dual-target weight loss injection to AstraZeneca [4] - Domestic pharmaceutical companies, including HengRui Medicine, Hansoh Pharmaceutical, and Chengyi Biotechnology, have successfully expanded internationally through licensing their GLP-1 drugs [4] - The value of Chinese innovative drugs is being reassessed by multinational pharmaceutical companies, with next-generation weight loss drugs seen as a significant strategic focus due to their vast market potential [4] Group 4 - Goldman Sachs projected that the global market for GLP-1 drugs could reach $95 billion by 2030 and potentially expand to $120 billion by 2035 [4]